Cargando…

Behavioural and clinical predictors for Loiasis

BACKGROUND: Loiasis is a vector-borne disease in Central and West Africa. While there is still uncertainty to what extent loiasis is responsible for population morbidity, individuals having both loiasis and onchocerciasis have a high risk of fatal encephalopathy when treatment (ie, ivermectin) for o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mischlinger, Johannes, Veletzky, Luzia, Tazemda-Kuitsouc, Gildas B, Pitzinger, Paul, Matsegui, Pierre B, Gmeiner, Markus, Lagler, Heimo, Gebru, Tamirat, Held, Jana, Mordmüller, Benjamin, Ramharter, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Edinburgh University Global Health Society 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827628/
https://www.ncbi.nlm.nih.gov/pubmed/29497506
http://dx.doi.org/10.7189/jogh.08.010413
_version_ 1783302501316952064
author Mischlinger, Johannes
Veletzky, Luzia
Tazemda-Kuitsouc, Gildas B
Pitzinger, Paul
Matsegui, Pierre B
Gmeiner, Markus
Lagler, Heimo
Gebru, Tamirat
Held, Jana
Mordmüller, Benjamin
Ramharter, Michael
author_facet Mischlinger, Johannes
Veletzky, Luzia
Tazemda-Kuitsouc, Gildas B
Pitzinger, Paul
Matsegui, Pierre B
Gmeiner, Markus
Lagler, Heimo
Gebru, Tamirat
Held, Jana
Mordmüller, Benjamin
Ramharter, Michael
author_sort Mischlinger, Johannes
collection PubMed
description BACKGROUND: Loiasis is a vector-borne disease in Central and West Africa. While there is still uncertainty to what extent loiasis is responsible for population morbidity, individuals having both loiasis and onchocerciasis have a high risk of fatal encephalopathy when treatment (ie, ivermectin) for onchocerciasis is given. Therefore it is current policy that communities of high loiasis-burden are excluded from mass drug administration programmes of ivermectin. To address this treatment gap we present diagnostic scores, based on clinical and behavioural predictors that may help to rapidly identify sub-groups with loiasis within high-burden communities. METHODS: A cross-sectional survey was performed in the province of la Ngounie, Gabon between December 2015 and Februrary 2016 and 947 participants of all ages were recruited. Clinical parameters and behavioural exposure factors were ascertained by questionnaire-based interviews. Parasitological analysis of blood samples was performed for L. loa detection. Diagnostic scores consisting of clinical and behavioural factors were modelled to predict loiasis in sub-groups residing in endemic regions. RESULTS: Increasing sylvan exposure was identified as important risk factor for loiasis with adjusted odds ratios of 5.1 (95% confidence interval CI 2.6-9.9) for occasional forest exposure, 11.1 (95% CI 5.4-22.6) for frequent forest exposure and 25.7 (95% CI 12.5-52.9) for intensive forest exposure. Individuals with loiasis were 7.7 (95% CI 5.4-11.0) times more likely to report recurrent pruritus than those without loiasis. Reporting of regular daily exposure to the deep rain forest and recurrent pruritus was 9-fold (positive likelihood ratio 9.18; 95% CI: 6.39-13.18) more prevalent in individuals with loiasis than in controls. Concordantly, the absence of regular weekly forest exposure was associated with extremely low disease-likelihood (negative likelihood ratio 0.09; 95% CI 0.05-0.16). CONCLUSIONS: These composite scores may serve as a simple tool to rapidly identify both those most and those least at risk of disease and may simplify loiasis control activities as well as screening procedures for studies on loiasis. Further, they may aid policy-makers to tailor the delivery of ivermectin mass drug administration for onchocerciasis control programmes more effectively and safely in regions of high loiasis-burden.
format Online
Article
Text
id pubmed-5827628
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Edinburgh University Global Health Society
record_format MEDLINE/PubMed
spelling pubmed-58276282018-03-01 Behavioural and clinical predictors for Loiasis Mischlinger, Johannes Veletzky, Luzia Tazemda-Kuitsouc, Gildas B Pitzinger, Paul Matsegui, Pierre B Gmeiner, Markus Lagler, Heimo Gebru, Tamirat Held, Jana Mordmüller, Benjamin Ramharter, Michael J Glob Health Articles BACKGROUND: Loiasis is a vector-borne disease in Central and West Africa. While there is still uncertainty to what extent loiasis is responsible for population morbidity, individuals having both loiasis and onchocerciasis have a high risk of fatal encephalopathy when treatment (ie, ivermectin) for onchocerciasis is given. Therefore it is current policy that communities of high loiasis-burden are excluded from mass drug administration programmes of ivermectin. To address this treatment gap we present diagnostic scores, based on clinical and behavioural predictors that may help to rapidly identify sub-groups with loiasis within high-burden communities. METHODS: A cross-sectional survey was performed in the province of la Ngounie, Gabon between December 2015 and Februrary 2016 and 947 participants of all ages were recruited. Clinical parameters and behavioural exposure factors were ascertained by questionnaire-based interviews. Parasitological analysis of blood samples was performed for L. loa detection. Diagnostic scores consisting of clinical and behavioural factors were modelled to predict loiasis in sub-groups residing in endemic regions. RESULTS: Increasing sylvan exposure was identified as important risk factor for loiasis with adjusted odds ratios of 5.1 (95% confidence interval CI 2.6-9.9) for occasional forest exposure, 11.1 (95% CI 5.4-22.6) for frequent forest exposure and 25.7 (95% CI 12.5-52.9) for intensive forest exposure. Individuals with loiasis were 7.7 (95% CI 5.4-11.0) times more likely to report recurrent pruritus than those without loiasis. Reporting of regular daily exposure to the deep rain forest and recurrent pruritus was 9-fold (positive likelihood ratio 9.18; 95% CI: 6.39-13.18) more prevalent in individuals with loiasis than in controls. Concordantly, the absence of regular weekly forest exposure was associated with extremely low disease-likelihood (negative likelihood ratio 0.09; 95% CI 0.05-0.16). CONCLUSIONS: These composite scores may serve as a simple tool to rapidly identify both those most and those least at risk of disease and may simplify loiasis control activities as well as screening procedures for studies on loiasis. Further, they may aid policy-makers to tailor the delivery of ivermectin mass drug administration for onchocerciasis control programmes more effectively and safely in regions of high loiasis-burden. Edinburgh University Global Health Society 2018-06 2018-02-27 /pmc/articles/PMC5827628/ /pubmed/29497506 http://dx.doi.org/10.7189/jogh.08.010413 Text en Copyright © 2018 by the Journal of Global Health. All rights reserved. http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License.
spellingShingle Articles
Mischlinger, Johannes
Veletzky, Luzia
Tazemda-Kuitsouc, Gildas B
Pitzinger, Paul
Matsegui, Pierre B
Gmeiner, Markus
Lagler, Heimo
Gebru, Tamirat
Held, Jana
Mordmüller, Benjamin
Ramharter, Michael
Behavioural and clinical predictors for Loiasis
title Behavioural and clinical predictors for Loiasis
title_full Behavioural and clinical predictors for Loiasis
title_fullStr Behavioural and clinical predictors for Loiasis
title_full_unstemmed Behavioural and clinical predictors for Loiasis
title_short Behavioural and clinical predictors for Loiasis
title_sort behavioural and clinical predictors for loiasis
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5827628/
https://www.ncbi.nlm.nih.gov/pubmed/29497506
http://dx.doi.org/10.7189/jogh.08.010413
work_keys_str_mv AT mischlingerjohannes behaviouralandclinicalpredictorsforloiasis
AT veletzkyluzia behaviouralandclinicalpredictorsforloiasis
AT tazemdakuitsoucgildasb behaviouralandclinicalpredictorsforloiasis
AT pitzingerpaul behaviouralandclinicalpredictorsforloiasis
AT matseguipierreb behaviouralandclinicalpredictorsforloiasis
AT gmeinermarkus behaviouralandclinicalpredictorsforloiasis
AT laglerheimo behaviouralandclinicalpredictorsforloiasis
AT gebrutamirat behaviouralandclinicalpredictorsforloiasis
AT heldjana behaviouralandclinicalpredictorsforloiasis
AT mordmullerbenjamin behaviouralandclinicalpredictorsforloiasis
AT ramhartermichael behaviouralandclinicalpredictorsforloiasis